Skip to main content
Erschienen in: Tumor Biology 5/2014

01.05.2014 | Research Article

The mannose-sensitive hemagglutination pilus strain of Pseudomonas aeruginosa shift peritoneal milky spot macrophages towards an M1 phenotype to dampen peritoneal dissemination

verfasst von: Zhi-Feng Miao, Ting-Ting Zhao, Feng Miao, Zhen-Ning Wang, Ying-Ying Xu, Xiao-Yun Mao, Jian Gao, Jian-Hua Wu, Xing-Yu Liu, Yi You, Hao Xu, Hui-Mian Xu

Erschienen in: Tumor Biology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Peritoneal dissemination (PD) of tumor cells is the most frequent pattern of gastric cancer recurrence and the leading cause of death. Peritoneal milky spots are deemed as the site of origin of gastric cancer PD wherein the main cellular components are macrophages. A vaccine derived from the mannose-sensitive hemagglutination pilus strain of Pseudomonas aeruginosa (PA-MSHA) has exhibit strong immune modulatory properties. In the present study, we tested the hypothesis whether the PA-MSHA vaccine activated peritoneal milky spot macrophages (PMSM) in a manner that would attenuate PD. It was observed that PA-MSHA activated PMSM towards a classical activation phenotype via a toll-like receptor4/9-dependent mechanism, which increased interleukin-12 levels and promoted the expression of co-stimulatory and antigen-presenting molecules like CD80, CD86, and MHC-II (P < 0.05). In addition, PA-MSHA-treated PMSM exhibited strong nonspecific antitumor effects in both contact-dependent and contact-independent modes of action (P < 0.05). In mice treated with PA-MSHA before inoculating gastric cancer cells, we noted alleviated PD toward the untreated mice. In conclusion, our findings demonstrated that PA-MSHA can stimulate PMSM towards an M1 phenotype and that activated PMSM inhibit gastric cancer growth and PD both in vitro and in vivo. The results of the current study provide a mechanistic insight that is relevant to the potential application of PA-MSHA in the treatment of gastric cancer-mediated PD.
Literatur
1.
Zurück zum Zitat Catalano V, Labianca R, Beretta GD, et al. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127–64.CrossRefPubMed Catalano V, Labianca R, Beretta GD, et al. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127–64.CrossRefPubMed
3.
Zurück zum Zitat Jackson C, Cunningham D, Oliveira J, et al. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:34–6.CrossRefPubMed Jackson C, Cunningham D, Oliveira J, et al. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:34–6.CrossRefPubMed
4.
Zurück zum Zitat Buzzoni R, Bajetta E, Di Bartolomeo M, et al. Pathological features as predictors of recurrence after radical resection of gastric cancer. Br J Surg. 2006;93:205–9.CrossRefPubMed Buzzoni R, Bajetta E, Di Bartolomeo M, et al. Pathological features as predictors of recurrence after radical resection of gastric cancer. Br J Surg. 2006;93:205–9.CrossRefPubMed
5.
Zurück zum Zitat Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009;96:26–33.CrossRefPubMed Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009;96:26–33.CrossRefPubMed
6.
Zurück zum Zitat Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692–8.CrossRefPubMed Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692–8.CrossRefPubMed
7.
Zurück zum Zitat Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21:233–48.CrossRefPubMed Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21:233–48.CrossRefPubMed
8.
Zurück zum Zitat Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 2011;98:1225–35.CrossRefPubMed Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 2011;98:1225–35.CrossRefPubMed
9.
Zurück zum Zitat Mebius RE. Lymphoid organs for peritoneal cavity immune response: milky spots. Immunity. 2009;30:670–2.CrossRefPubMed Mebius RE. Lymphoid organs for peritoneal cavity immune response: milky spots. Immunity. 2009;30:670–2.CrossRefPubMed
10.
Zurück zum Zitat Krist LF, Kerremans M, Broekhuis-Fluitsma DM, et al. Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother. 1998;47:205–12.CrossRefPubMed Krist LF, Kerremans M, Broekhuis-Fluitsma DM, et al. Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother. 1998;47:205–12.CrossRefPubMed
11.
Zurück zum Zitat Khan SM, Funk HM, Thiolloy S, et al. In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin Exp Metastasis. 2010;27:185–96.CrossRefPubMed Khan SM, Funk HM, Thiolloy S, et al. In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin Exp Metastasis. 2010;27:185–96.CrossRefPubMed
12.
Zurück zum Zitat Cao L, Hu X, Zhang Y, et al. Omental milky spots in screening gastric cancer stem cells. Neoplasma. 2011;58:20–6.CrossRefPubMed Cao L, Hu X, Zhang Y, et al. Omental milky spots in screening gastric cancer stem cells. Neoplasma. 2011;58:20–6.CrossRefPubMed
13.
Zurück zum Zitat Sorensen EW, Gerber SA, Sedlacek AL, et al. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res. 2009;45:185–94.CrossRefPubMed Sorensen EW, Gerber SA, Sedlacek AL, et al. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res. 2009;45:185–94.CrossRefPubMed
14.
Zurück zum Zitat Oosterling SJ, van der Bij GJ, Bögels M, et al. Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease. Cancer Immunol Immunother. 2006;55:1043–51.CrossRefPubMed Oosterling SJ, van der Bij GJ, Bögels M, et al. Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease. Cancer Immunol Immunother. 2006;55:1043–51.CrossRefPubMed
15.
Zurück zum Zitat Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96.CrossRefPubMed Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96.CrossRefPubMed
16.
Zurück zum Zitat Koido S, Homma S, Okamoto M. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS One. 2013;8:e59280.CrossRefPubMedPubMedCentral Koido S, Homma S, Okamoto M. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS One. 2013;8:e59280.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Liu W, O'Donnell MA, Chen X, et al. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother. 2009;58:1647–55.CrossRefPubMed Liu W, O'Donnell MA, Chen X, et al. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother. 2009;58:1647–55.CrossRefPubMed
18.
Zurück zum Zitat Byeon SE, Lee J, Kim JH et al. Molecular mechanism of macrophage activation by red ginseng acidic polysaccharide from Korean red ginseng. Mediators Inflamm 2012:732860. Byeon SE, Lee J, Kim JH et al. Molecular mechanism of macrophage activation by red ginseng acidic polysaccharide from Korean red ginseng. Mediators Inflamm 2012:732860.
19.
Zurück zum Zitat Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006;24:3164–71.CrossRefPubMed Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006;24:3164–71.CrossRefPubMed
20.
Zurück zum Zitat Zhang J, Tang Q, Zhou C, et al. GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response. Life Sci. 2010;87:628–37.CrossRefPubMed Zhang J, Tang Q, Zhou C, et al. GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response. Life Sci. 2010;87:628–37.CrossRefPubMed
21.
Zurück zum Zitat Cao Z, Shi L, Li Y, et al. Pseudomonas aeruginosa: mannose sensitive hemagglutinin inhibits the growth of human hepatocarcinoma cells via mannose-mediated apoptosis. Dig Dis Sci. 2009;54:2118–27.CrossRefPubMed Cao Z, Shi L, Li Y, et al. Pseudomonas aeruginosa: mannose sensitive hemagglutinin inhibits the growth of human hepatocarcinoma cells via mannose-mediated apoptosis. Dig Dis Sci. 2009;54:2118–27.CrossRefPubMed
22.
Zurück zum Zitat Liu ZB, Hou YF, Zhu J, et al. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene. 2010;29:2996–3009.CrossRefPubMed Liu ZB, Hou YF, Zhu J, et al. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene. 2010;29:2996–3009.CrossRefPubMed
23.
Zurück zum Zitat Liu ZB, Hou YF, Min-Dong, et al. PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem. 2009;108:195–206.CrossRefPubMed Liu ZB, Hou YF, Min-Dong, et al. PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem. 2009;108:195–206.CrossRefPubMed
24.
Zurück zum Zitat Zhu YP, Bian XJ, Ye DW, et al. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits proliferation and induces apoptosis in a caspase-dependent manner in human bladder cancer cell lines. Oncol Lett. 2013;5:1357–62.PubMedPubMedCentral Zhu YP, Bian XJ, Ye DW, et al. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits proliferation and induces apoptosis in a caspase-dependent manner in human bladder cancer cell lines. Oncol Lett. 2013;5:1357–62.PubMedPubMedCentral
25.
Zurück zum Zitat Hou J, Liu Y, Liu Y, Shao Y. The MSHA strain of Pseudomonas aeruginosa activated TLR pathway and enhanced HIV-1 DNA vaccine immunoreactivity. PLoS One. 2012;7:e47724.CrossRefPubMedPubMedCentral Hou J, Liu Y, Liu Y, Shao Y. The MSHA strain of Pseudomonas aeruginosa activated TLR pathway and enhanced HIV-1 DNA vaccine immunoreactivity. PLoS One. 2012;7:e47724.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Soudi S, Zavaran-Hosseini A, Muhammad Hassan Z, et al. Comparative study of the effect of LPS on the function of BALB/c and C57BL/6 peritoneal macrophages. Cell J. 2013;15:45–54.PubMedPubMedCentral Soudi S, Zavaran-Hosseini A, Muhammad Hassan Z, et al. Comparative study of the effect of LPS on the function of BALB/c and C57BL/6 peritoneal macrophages. Cell J. 2013;15:45–54.PubMedPubMedCentral
27.
Zurück zum Zitat Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167:195–205.CrossRefPubMedPubMedCentral Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167:195–205.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Hallam S, Escorcio-Correia M, Soper R, et al. Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol. 2009;219:143–52.CrossRefPubMedPubMedCentral Hallam S, Escorcio-Correia M, Soper R, et al. Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol. 2009;219:143–52.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Dumitru CD, Antonysamy MA, Gorski KS, et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother. 2009;58:575–87.CrossRefPubMed Dumitru CD, Antonysamy MA, Gorski KS, et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother. 2009;58:575–87.CrossRefPubMed
31.
Zurück zum Zitat Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev. 2008;226:41–56.CrossRefPubMedPubMedCentral Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev. 2008;226:41–56.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Pinto A, Morello S, Sorrentino R. Lung cancer and Toll-like receptors. Cancer Immunol Immunother. 2011;60:1211–20.CrossRefPubMed Pinto A, Morello S, Sorrentino R. Lung cancer and Toll-like receptors. Cancer Immunol Immunother. 2011;60:1211–20.CrossRefPubMed
Metadaten
Titel
The mannose-sensitive hemagglutination pilus strain of Pseudomonas aeruginosa shift peritoneal milky spot macrophages towards an M1 phenotype to dampen peritoneal dissemination
verfasst von
Zhi-Feng Miao
Ting-Ting Zhao
Feng Miao
Zhen-Ning Wang
Ying-Ying Xu
Xiao-Yun Mao
Jian Gao
Jian-Hua Wu
Xing-Yu Liu
Yi You
Hao Xu
Hui-Mian Xu
Publikationsdatum
01.05.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1559-4

Weitere Artikel der Ausgabe 5/2014

Tumor Biology 5/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.